CHAPMAN, Rebecca J, David R GHASEMI, Felipe ANDREIUOLO, Valentina ZSCHERNACK, Tauziede Espariat ARNAULT, Francesca R BUTTARELLI, Felice GIANGASPERO, Jacques GRILL, Christine HABERLER, Simon M L PAINE, Ian SCOTT, Thomas S JACQUES, Martin SILL, Stefan PFISTER, John-Paul KILDAY, Pierre LEBLOND, Maura MASSIMINO, Hendrik WITT, Piergiorgio MODENA, Pascale VARLET, Torsten PIETSCH, Richard G GRUNDY, Kristian W PAJTLER a Timothy A RITZMANN. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study. Neuro-Oncology. Cary: Oxford University Press, 2023, roč. 25, č. 10, s. 1871-1882. ISSN 1522-8517. Dostupné z: https://dx.doi.org/10.1093/neuonc/noad055.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study
Autoři CHAPMAN, Rebecca J, David R GHASEMI, Felipe ANDREIUOLO, Valentina ZSCHERNACK, Tauziede Espariat ARNAULT, Francesca R BUTTARELLI, Felice GIANGASPERO, Jacques GRILL, Christine HABERLER, Simon M L PAINE, Ian SCOTT, Thomas S JACQUES, Martin SILL, Stefan PFISTER, John-Paul KILDAY, Pierre LEBLOND, Maura MASSIMINO, Hendrik WITT, Piergiorgio MODENA, Pascale VARLET, Torsten PIETSCH, Richard G GRUNDY, Kristian W PAJTLER a Timothy A RITZMANN.
Vydání Neuro-Oncology, Cary, Oxford University Press, 2023, 1522-8517.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30230 Other clinical medicine subjects
Stát vydavatele Velká Británie a Severní Irsko
Utajení není předmětem státního či obchodního tajemství
WWW SIOP
Impakt faktor Impact factor: 15.900 v roce 2022
Kód RIV RIV/00216224:90249/23:00132051
Organizační jednotka CZECRIN IV
Doi http://dx.doi.org/10.1093/neuonc/noad055
UT WoS 000989756200001
Klíčová slova česky brain tumors; biomarkers; Ependymoma; neuro-oncology; paediatric
Klíčová slova anglicky brain tumors; biomarkers; Ependymoma; neuro-oncology; paediatric
Štítky Excelence Science, INT, neMU
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnil: Mgr. Michal Petr, učo 65024. Změněno: 12. 4. 2024 12:59.
Anotace
Background Accurate identification of brain tumor molecular subgroups is increasingly important. We aimed to establish the most accurate and reproducible ependymoma subgroup biomarker detection techniques, across 147 cases from International Society of Pediatric Oncology (SIOP) Ependymoma II trial participants, enrolled in the pan-European "Biomarkers of Ependymoma in Children and Adolescents (BIOMECA)" study. Methods Across 6 European BIOMECA laboratories, we evaluated epigenetic profiling (DNA methylation array); immunohistochemistry (IHC) for nuclear p65-RELA, H3K27me3, and Tenascin-C; copy number analysis via fluorescent in situ hybridization (FISH) and MLPA (1q, CDKN2A), and MIP and DNA methylation array (genome-wide copy number evaluation); analysis of ZFTA- and YAP1-fusions by RT-PCR and sequencing, Nanostring and break-apart FISH. Results DNA Methylation profiling classified 65.3% (n = 96/147) of cases as EPN-PFA and 15% (n = 22/147) as ST-ZFTA fusion-positive. Immunohistochemical loss of H3K27me3 was a reproducible and accurate surrogate marker for EPN-PFA (sensitivity 99%-100% across 3 centers). IHC for p65-RELA, FISH, and RNA-based analyses effectively identified ZFTA- and YAP-fused supratentorial ependymomas. Detection of 1q gain using FISH exhibited only 57% inter-center concordance and low sensitivity and specificity while MIP, MLPA, and DNA methylation-based approaches demonstrated greater accuracy. Conclusions We confirm, in a prospective trial cohort, that H3K27me3 immunohistochemistry is a robust EPN-PFA biomarker. Tenascin-C should be abandoned as a PFA marker. DNA methylation and MIP arrays are effective tools for copy number analysis of 1q gain, 6q, and CDKN2A loss while FISH is inadequate. Fusion detection was successful, but rare novel fusions need more extensive technologies. Finally, we propose test sets to guide future diagnostic approaches.
Návaznosti
90249, velká výzkumná infrastrukturaNázev: CZECRIN IV
VytisknoutZobrazeno: 21. 7. 2024 04:38